Novo Nordisk and Amazon Web Services (AWS) are joining forces in a strategic partnership aimed at accelerating drug discovery, modernising operations and using agentic AI to shorten the journey from drug target to first human dose.
The companies have established a new co-innovation hub in London, bringing together engineers and scientists from both organisations to combine AWS artificial intelligence technologies with Novo Nordisk’s scientific data and expertise.
“Partnering with AWS is about making AI a driver of innovation across Novo Nordisk,” said Mike Doustdar, president and CEO of Novo Nordisk.
“By combining our scientific expertise with AWS’ tools and purpose-built services for the life sciences industry, while also creating a dedicated co-innovation hub within our existing facility in London, we are accelerating discovery and developing responsible AI solutions that will create real progress for people living with serious chronic diseases.”
Novo Nordisk has selected AWS as its preferred cloud provider and strategic AI partner, pairing its deep expertise in chronic diseases with AWS’s cloud infrastructure, AI capabilities and life sciences technologies.
The collaboration is already delivering results, with Novo Nordisk reporting reduced clinical documentation time and increased productivity among more than 25,000 employees.
The expanded partnership will create secure technology foundations designed to move promising ideas more rapidly toward new therapies. The companies plan to use technologies including Amazon Bio Discovery and Amazon Bedrock to help identify drug targets, accelerate therapy design and connect genomic, imaging and clinical data.
The goal is to allow discoveries made in early-stage research to inform clinical trial design more quickly, potentially compressing development timelines across therapeutic areas.
Novo Nordisk will also deploy Amazon Bedrock AgentCore to introduce AI agents into its operations, with the aim of automating processes and improving efficiency at scale.
"Every part of our work with Novo Nordisk comes back to one thing: getting the right medicine to patients, faster," said Matt Garman, CEO, AWS.
"Novo Nordisk has chosen AWS as their strategic AI partner to fundamentally change how medicines are discovered and developed using services such as Amazon Bio Discovery and Amazon Bedrock. We’re excited to partner with Novo Nordisk so that these technologies, AWS Forward Deployed Engineers, and Novo Nordisk’s industry-leading science teams can help compress drug discovery timelines, securely process complex datasets, and scale findings across therapeutic areas.”
The partnership also builds on Novo Nordisk’s wider collaboration with Amazon businesses serving the healthcare sector, including Amazon Pharmacy, Amazon Ads and Amazon One Medical, as the companies seek to reshape how therapies are discovered, developed and ultimately delivered to patients.
